CAFERGOT TAB 100 MG
CAFFEINE : 100 MG ERGOTAMINE TARTRATE : 1 MG · DIN 00176095 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is CAFERGOT TAB?
CAFERGOT TAB 100 MG contains CAFFEINE : 100 MG ERGOTAMINE TARTRATE : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 00176095, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Mar-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CAFERGOT TAB used for?
CAFERGOT* (ergotamine tartrate and caffeine) may be used for the clinical management of acute attacks of migraine with or without aura. CAFERGOT* Tablets are not intended for the prophylactic therapy of migraine or for use in the management of sporadic hemiplegic, basilar-type, or ophthalmoplegic migraine.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00176095 |
|---|---|
| Brand name | CAFERGOT TAB |
| Generic / active ingredient | CAFFEINE : 100 MG ERGOTAMINE TARTRATE : 1 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N02CA52 ERGOTAMINE, COMBINATIONS EXCL. PSYCHOLEPTICS |
| AHFS class | 12:16.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Mar-2014 |
| Original market date | 1951-12-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code N02CA52 ERGOTAMINE, COMBINATIONS EXCL. PSYCHOLEPTICS. 0 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CAFERGOT SUP | 100 MG | SUPPOSITORY | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 00782920 |
| ERGODRYL CAP | 25 MG | CAPSULE | ERFA CANADA 2012 INC | CANCELLED POST MARKET | DIN 00156086 |
| MEGRAL TABS | 100 MG | TABLET | GLAXO WELLCOME INC. | CANCELLED POST MARKET | DIN 00068586 |
| WIGRAINE SUPPOSITORIES | 1 MG | SUPPOSITORY | ORGANON CANADA LTD LTEE | CANCELLED POST MARKET | DIN 00489212 |
| WIGRAINE TAB | .1 MG | TABLET | ORGANON CANADA LTD LTEE | CANCELLED POST MARKET | DIN 00489220 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.